RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $182
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $142 to $182.
June 21, 2024 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Sarepta Therapeutics and raises the price target from $142 to $182.
The raised price target from $142 to $182 by RBC Capital suggests a positive outlook for Sarepta Therapeutics, which could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100